- cafead   Aug 03, 2020 at 10:22: AM
via Preclinical protein degradation biotech Kymera Therapeutics has a great year, nabbing a $102 million round for its march to the clinic, as well as a major tie up with French Big Pharma Sanofi.
Now, like so many of its early-stage peers, the Cambridge, Massachusetts-based biotech is seeking an initial public offering (IPO) worth a cool $100 million, though if it follows the current biotech IPO trend, this could be much higher.
article source
Now, like so many of its early-stage peers, the Cambridge, Massachusetts-based biotech is seeking an initial public offering (IPO) worth a cool $100 million, though if it follows the current biotech IPO trend, this could be much higher.
article source